Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells

The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Yasufumi, Yamauchi, Takahiro, Hosono, Naoko, Uzui, Kanako, Negoro, Eiju, Morinaga, Koji, Nishi, Rie, Yoshida, Akira, Kimura, Shinya, Maekawa, Taira, Ueda, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://www.ncbi.nlm.nih.gov/pubmed/27166836
http://dx.doi.org/10.1111/cas.12965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://www.ncbi.nlm.nih.gov/pubmed/27166836
http://dx.doi.org/10.1111/cas.12965

Ejemplares similares